Current status of atezolizumab combined with bevacizumab in the treatment of hepatocellular carcinoma

VernacularTitle:阿替利珠单抗联合贝伐珠单抗治疗肝细胞癌的现状
Author: Yaming GUO ¹ ; Xing ZHU ; Chaoliu DAI ; Feng XU
Author Information

1. 中国医科大学附属盛京医院普通外科，沈阳　110004
Keywords: Carcinoma, hepatocellular; Atezolizumab; Bevacizumab; Immunotherapy
From: Chinese Journal of Hepatobiliary Surgery 2022;28(10):789-792
CountryChina
Language:Chinese
Abstract: Hepatocellular carcinoma (HCC) has a hidden onset and rapid progress. Most of the patients have lost the opportunity of surgery at the onset, and the systemic treatment effect is not satisfactory. In recent years, immune checkpoint inhibitors combined with targeted therapy have brought hope to HCC patients. In particular, treatment with atezolizumab combined with bevacizumab has been recommended by many domestic and foreign guidelines as the first-line treatment for patients with unresectable HCC who have not previously received systematic treatment. In this review, the application status of atezolizumab plus bevacizumab, coping strategies for treatment failure, cost-benefit analysis and side effects were described in order to provide reference for clinical treatment.